That you think that NWBO will be able to finance all the many trials as described in their 10Q's/K, continue to finance Advent, set up a marketing and sales team, initiate the pediatric trial etc etc by diluting retail for USD 100's of millions more is both delusional and naive. NWBO will be either injected with 100's of millions of USD for a license deal or better yet (what I am predicting as I have said many time here) be bought out OR perish after MHRA approval.
90% of non-revenue biotech are bought out after approval NWBO is on top of that list
Market Data 
Markets 
AI
